CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 4,763	$ 2,272
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	33,266	32,223
Provision for bad debts	23,500	22,630
Gain on return of common stock	0	(5,032)
Equity in earnings of joint ventures	(4,922)	(5,553)
Distributions from joint ventures	3,993	2,098
Amortization of deferred financing costs and loan discount	1,636	2,738
Loss on sale and disposal of equipment	408	441
Gain on sale of imaging centers	(2,301)	0
Stock-based compensation	4,314	3,761
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable	(29,445)	(24,873)
Other current assets	4,553	8,454
Other assets	(835)	220
Deferred taxes	1,940	10
Deferred rent	1,830	1,052
Deferred revenue	445	0
Accounts payable, accrued expenses and other	7,014	10,983
Net cash provided by operating activities	50,159	51,424
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities	(9,904)	(6,603)
Investment at cost	(500)	0
Purchase of property and equipment	(42,647)	(40,267)
Proceeds from sale of equipment	63	63
Proceeds from sale of imaging facilities	5,627	0
Cash contribution from partner in JV formation	1,473	994
Equity contributions in existing and purchase of interest in joint ventures	(80)	(734)
Net cash used in investing activities	(45,968)	(46,547)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable	(3,769)	(6,310)
Payments on Term Loan Debt/Senior Notes	(12,125)	(12,357)
Deferred financing costs and debt discount	(570)	0
Distributions paid to noncontrolling interests	(655)	(157)
Proceeds from the sale of non-controlling interests, net of taxes	4,850	0
Contributions from noncontrolling partners	125	0
Proceeds on revolving credit facility	139,400	235,500
Payments on revolving credit facility	(139,400)	(221,700)
Proceeds from issuance of common stock upon exercise of options	0	150
Net cash used in financing activities	(12,144)	(4,874)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	22	(16)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(7,931)	(13)
CASH AND CASH EQUIVALENTS, beginning of period	20,638	446
CASH AND CASH EQUIVALENTS, end of period	12,707	433
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest	19,023	18,545
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Purchase of equipment and leasehold improvements not yet paid for	17,500	15,400
Capital lease debt related to radiology equipment	5,200	1,300
Investment in joint venture	3,000	0
Transfer of fixed assets to new joint venture	$ 2,500	$ 0